---
title: "IFRX.US (IFRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IFRX.US/news.md"
symbol: "IFRX.US"
name: "IFRX.US"
parent: "https://longbridge.com/en/quote/IFRX.US.md"
datetime: "2026-05-20T05:16:49.718Z"
locales:
  - [en](https://longbridge.com/en/quote/IFRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IFRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IFRX.US/news.md)
---

# IFRX.US (IFRX.US) — Related News

### [InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline](https://longbridge.com/en/news/285751166.md)
*2026-05-08T15:53:13.000Z*
> InflaRx (NASDAQ: IFRX) is prioritizing the development of izicopan, an oral C5a receptor inhibitor, for ANCA-associated 

### [InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares](https://longbridge.com/en/news/285725744.md)
*2026-05-08T12:17:22.000Z*
> Jena, Germany - InflaRx N.V., a leading biopharmaceutical company focused on developing anti-inflammatory treatments for

### [InflaRx (NASDAQ:IFRX) Posts Earnings Results, Beats Estimates By $0.08 EPS](https://longbridge.com/en/news/285483398.md)
*2026-05-07T04:24:08.000Z*
> InflaRx (NASDAQ:IFRX) reported quarterly earnings of ($0.09) EPS, surpassing estimates of ($0.17) by $0.08. Following th

### [12 Industrials Stocks Moving In Wednesday's Intraday Session](https://longbridge.com/en/news/285416085.md)
*2026-05-06T17:05:45.000Z*
> In Wednesday's trading session, BlueLinx Holdings (NYSE:BXC) saw a significant gain of 28.8%, reaching $59.5, following 

### [](https://longbridge.com/en/news/285398940.md)
*2026-05-06T14:40:31.000Z*
> InflaRx shares are trading higher after the company announced that it intends to develop izicopan, an oral C5a receptor 

### [InflaRx completes pricing of $150 million common stock offering](https://longbridge.com/en/news/285396467.md)
*2026-05-06T14:25:36.000Z*
> InflaRx N.V. announced the issuance of 75 million shares of common stock at a price of $2.00 per share, raising approxim

### [InflaRx Files Q1 2026 Financials with SEC via Form 6-K](https://longbridge.com/en/news/285382696.md)
*2026-05-06T12:24:38.000Z*
> InflaRx N.V. has filed a Form 6-K with the SEC for Q1 2026, including unaudited financial statements and management anal

### [InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases | IFRX Stock News](https://longbridge.com/en/news/285377138.md)
*2026-05-06T04:25:30.000Z*
> InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases | IFRX Stock News

### [InfraRX Down Ahead of Next Quarterly Report](https://longbridge.com/en/news/284910776.md)
*2026-05-01T14:32:22.000Z*
> InflaRx N.V. (NASDAQ: IFRX) opened lower ahead of its Q1 2026 financial report, set for May 7. The biopharmaceutical com

### [InflaRx to Report First Quarter 2026 Results on May 7, 2026 | IFRX Stock News](https://longbridge.com/en/news/284892676.md)
*2026-05-01T03:30:00.000Z*
> InflaRx N.V. will report its financial and operating results for Q1 2026 on May 7, 2026, before market opening. The comp